IQV
IQVIA Holdings IncNYSE
Healthcare • Diagnostics & Research
Factor tilt: Large-Cap Blend
$271.83+2.62%
Close Nov 6, 2026
- Market cap
- $45.37B
- 1 month
- +5.0%
- 3 months
- +12.3%
- 1 year
- +29.4%
- 52-week range
- $156.66$279.36
- Dividend
- No dividends on record
- Short interest
- 1.9% of float3M shares · settled Oct 15, 2026 · -7.0% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $17.31B
- Net income
- $1.39B
- Free cash flow
- $2.08B
- Book value
- $6.66B
- Total debt
- $16.31B
- P/E
- 32.5×
- Price / sales
- 2.6×
- Price / book
- 6.8×
- FCF yield
- +4.6%
- Net margin
- +8.1%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About IQVIA Holdings Inc
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read more
The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
- Website
- iqvia.com
- Headquarters
- Durham, NC, United States
- Employees
- 95,000
- Listed
- May 9, 2013
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 6, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Oct 27, 2026 | $4.4B | +8.0% | 33.8% | $572.0M | $350.0M |
| Jun 2026filed Jul 28, 2026 | $4.4B | +8.7% | 32.9% | $506.0M | $256.0M |
| Mar 2026filed May 5, 2026 | $4.2B | +8.4% | 32.6% | $514.0M | $274.0M |
| Dec 2025filed Feb 17, 2026 | $4.4B | +10.3% | 6.7% | $732.0M | $514.0M |
| Sep 2025filed Oct 28, 2025 | $4.1B | +5.2% | 33.5% | $553.0M | $331.0M |
| Jun 2025filed Jul 22, 2025 | $4.0B | +5.3% | 32.9% | $506.0M | $266.0M |
| Mar 2025filed May 6, 2025 | $3.8B | +2.5% | 33.9% | $496.0M | $249.0M |
| Dec 2024filed Feb 13, 2025 | $4.0B | +2.3% | 34.8% | $626.0M | $437.0M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 17, 2026 | $16.3B | +5.9% | 33.3% | $2.2B | $1.4B |
| Dec 2024filed Feb 13, 2025 | $15.4B | +2.8% | 34.9% | $2.2B | $1.4B |
| Dec 2023filed Feb 15, 2024 | $15.0B | +4.0% | 35.0% | $2.0B | $1.4B |
| Dec 2022filed Feb 15, 2023 | $14.4B | +3.9% | 34.9% | $1.8B | $1.1B |
| Dec 2021filed Feb 16, 2022 | $13.9B | +22.1% | 33.5% | $1.4B | $966.0M |
| Dec 2020filed Feb 12, 2021 | $11.4B | +2.4% | 34.0% | $731.0M | $279.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched IQV. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
2,992,152 shares short
-223,967 shares (-7%) vs Sep 30, 2026
1.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
3,216,119 shares short
-900,403 shares (-21.9%) vs Sep 15, 2026
2.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
4,116,522 shares short
+339,173 shares (+9%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
3,777,349 shares short
-472,157 shares (-11.1%) vs Aug 14, 2026
2.4% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
4,249,506 shares short
-309,671 shares (-6.8%) vs Jul 31, 2026
2.7% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
4,559,177 shares short
-700,833 shares (-13.3%) vs Jul 15, 2026
2.9% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind IQV’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if IQV is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
115 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: sell 64 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
1,093 filers reported a long position in IQV for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
48.3%
of the 156.8M shares 13-F filers reported
Moves vs Q1 2026
5 added5 trimmed
Net shares held
0%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $2.8B · 14.5M shares | 14.5M | -3.2% |
| 2 | HARRIS ASSOCIATES L P | $2.4B · 12.2M shares | 12.2M | 0% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $2.1B · 10.9M shares | 10.9M | -1.1% |
| 4 | STATE STREET CORP | $1.5B · 7.5M shares | 7.5M | +0.4% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | $1.4B · 7.5M shares | 7.5M | -1% |
| 6 | JPMORGAN CHASE & CO | $1.2B · 6.1M shares | 6.1M | +13.5% |
| 7 | Artisan Partners Limited Partnership | $916.5M · 4.7M shares | 4.7M | -6.2% |
| 8 | Boston Partners | $865.5M · 4.5M shares | 4.5M | +5.4% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $857.2M · 4.5M shares | 4.5M | -0.2% |
| 10 | Invesco Ltd. | $632.8M · 3.3M shares | 3.3M | +0.4% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of IQV file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Apr 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 7.49% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for IQV
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.